Human BST2 inhibits rabies virus release independently of cysteine-linked dimerization and asparagine-linked glycosylation.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
12
2022
accepted:
29
09
2023
medline:
6
11
2023
pubmed:
3
11
2023
entrez:
3
11
2023
Statut:
epublish
Résumé
The innate immune response is a first-line defense mechanism triggered by rabies virus (RABV). Interferon (IFN) signaling and ISG products have been shown to confer resistance to RABV at various stages of the virus's life cycle. Human tetherin, also known as bone marrow stromal cell antigen 2 (hBST2), is a multifunctional transmembrane glycoprotein induced by IFN that has been shown to effectively counteract many viruses through diverse mechanisms. Here, we demonstrate that hBST2 inhibits RABV budding by tethering new virions to the cell surface. It was observed that release of virus-like particles (VLPs) formed by RABV G (RABV-G VLPs), but not RABV M (RABV-G VLPs), were suppressed by hBST2, indicating that RABV-G has a specific effect on the hBST2-mediated restriction of RABV. The ability of hBST2 to prevent the release of RABV-G VLPs and impede RABV growth kinetics is retained even when hBST2 has mutations at dimerization and/or glycosylation sites, making hBST2 an antagonist to RABV, with multiple mechanisms possibly contributing to the hBST2-mediated suppression of RABV. Our findings expand the knowledge of host antiviral mechanisms that control RABV infection.
Identifiants
pubmed: 37922253
doi: 10.1371/journal.pone.0292833
pii: PONE-D-22-33011
pmc: PMC10624315
doi:
Substances chimiques
Asparagine
7006-34-0
Cysteine
K848JZ4886
Bone Marrow Stromal Antigen 2
0
BST2 protein, human
0
Antigens, CD
0
GPI-Linked Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0292833Informations de copyright
Copyright: © 2023 Tanwattana et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cell Host Microbe. 2010 Apr 22;7(4):314-323
pubmed: 20399176
Structure. 2005 Jan;13(1):75-85
pubmed: 15642263
J Virol. 2017 Aug 10;91(17):
pubmed: 28637751
PLoS One. 2009 Sep 09;4(9):e6934
pubmed: 19742323
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2886-91
pubmed: 19179289
PLoS Pathog. 2010 Jul 22;6(7):e1001016
pubmed: 20661430
Viruses. 2020 Feb 16;12(2):
pubmed: 32079099
Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20889-94
pubmed: 19864625
Retrovirology. 2009 Sep 08;6:80
pubmed: 19737401
J Virol. 2010 May;84(9):4646-58
pubmed: 20147389
J Virol. 2003 Apr;77(7):3985-92
pubmed: 12634358
Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7229-34
pubmed: 17438267
Cell. 2009 Oct 30;139(3):499-511
pubmed: 19879838
Front Microbiol. 2011 Dec 12;2:250
pubmed: 22180752
Viruses. 2018 Jan 05;10(1):
pubmed: 29303997
Traffic. 2003 Oct;4(10):694-709
pubmed: 12956872
J Virol. 2011 Mar;85(6):2480-91
pubmed: 21209114
Vaccine. 2015 Aug 20;33(35):4238-46
pubmed: 25869890
Cell Host Microbe. 2008 Apr 17;3(4):245-52
pubmed: 18342597
J Virol. 2015 Dec;89(23):11820-33
pubmed: 26378163
Biochem Biophys Res Commun. 2014 Aug 8;450(4):1469-74
pubmed: 25019996
Retrovirology. 2015 Aug 07;12:67
pubmed: 26248668
J Virol. 2011 Oct;85(19):9708-15
pubmed: 21775449
Autophagy. 2020 Oct;16(10):1737-1752
pubmed: 31868081
Cell Host Microbe. 2012 Nov 15;12(5):633-44
pubmed: 23159053
PLoS Pathog. 2008 Dec;4(12):e1000251
pubmed: 19112510
PLoS One. 2015 Nov 13;10(11):e0142925
pubmed: 26566124
Int J Mol Sci. 2021 Nov 05;22(21):
pubmed: 34769416
J Virol. 1999 Jan;73(1):242-50
pubmed: 9847327
Curr HIV Res. 2012 Jun;10(4):321-6
pubmed: 22533471
J Virol. 1993 Jul;67(7):4415-20
pubmed: 8389938
Front Cell Infect Microbiol. 2022 Sep 13;12:979091
pubmed: 36176574
Vaccine. 2014 May 19;32(24):2799-804
pubmed: 24631077
PLoS Pathog. 2013;9(7):e1003483
pubmed: 23874200
J Virol. 2009 Oct;83(19):9672-81
pubmed: 19605472
J Neurovirol. 2015 Aug;21(4):370-82
pubmed: 25698500
J Virol. 1995 May;69(5):3156-60
pubmed: 7707543
Nature. 2008 Jan 24;451(7177):425-30
pubmed: 18200009
PLoS Negl Trop Dis. 2015 Apr 16;9(4):e0003709
pubmed: 25881058
PLoS Pathog. 2011 Nov;7(11):e1002332
pubmed: 22072961
J Biol Chem. 2015 Feb 6;290(6):3740-51
pubmed: 25525265
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18428-32
pubmed: 20940320
J Virol. 2020 Oct 14;94(21):
pubmed: 32796066
J Virol. 2009 Nov;83(22):11966-78
pubmed: 19740980
J Virol. 2013 Feb;87(4):2046-57
pubmed: 23221546
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18097-101
pubmed: 22025715
ChemistryOpen. 2021 Nov;10(11):1133-1141
pubmed: 34791819
J Virol. 2010 Dec;84(24):12646-57
pubmed: 20943977
Viruses. 2016 Feb 29;8(3):62
pubmed: 26938549
J Cell Sci. 2007 Nov 1;120(Pt 21):3850-8
pubmed: 17940069
Sci Rep. 2016 Jul 26;6:30529
pubmed: 27456665
Cell. 1996 Mar 22;84(6):941-51
pubmed: 8601317
J Virol. 2010 Oct;84(20):10569-80
pubmed: 20686043
J Neurovirol. 2000 Oct;6(5):373-81
pubmed: 11031690
J Virol. 2015 Nov;89(21):11011-8
pubmed: 26311886
J Virol. 2011 Jul;85(13):6657-68
pubmed: 21525357
J Virol. 2009 Mar;83(5):2382-5
pubmed: 19091864
J Virol. 2013 Nov;87(22):12327-38
pubmed: 24027304